



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.

Phone:040-23547532, Email : investors@natcopharma.co.in

CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Half Year ended September 30, 2021

(All amounts in ₹ millions except per share data)

| Sl. No. | Particulars | Quarter Ended | | Half Year Ended | | Year Ended |
|---------|--|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 30/09/2021 (Unaudited) | 30/09/2020 (Unaudited) | 30/09/2021 (Unaudited) | 30/09/2020 (Unaudited) | 31/03/2021 (Audited) |
| 1 | Revenue from operations | 3,772 | 8,022 | 7,875 | 13,656 | 20,521 |
| 2 | Net Profit for the period (before tax, exceptional and/or extraordinary items) | 698 | 2,707 | 1,608 | 4,288 | 5,796 |
| 3 | Net Profit for the period before tax (after exceptional and/or extraordinary items) | 698 | 2,707 | 1,608 | 4,288 | 5,796 |
| 4 | Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests | 651 | 2,024 | 1,401 | 3,252 | 4,409 |
| 5 | Total Comprehensive Income for the period attributable to owners of the parent | 583 | 1,979 | 1,401 | 3,228 | 4,496 |
| 6 | Paid-up Equity share capital of ₹2 each | 365 | 364 | 365 | 364 | 365 |
| 7 | Other equity (Revaluation reserve ₹ Nil) | - | - | - | - | 40,851 |
| 8 | Earnings Per Share (in Rupees) per ₹2/- share (non-annualised) | | | | | |
| | 1) Basic | 3.57 | 11.12 | 7.68 | 17.86 | 24.20 |
| | 2) Diluted | 3.57 | 11.09 | 7.67 | 17.81 | 24.16 |

Notes:

- Summarized Unaudited Standalone Financial Results of the Company is as under:

| Sl. No. | Particulars | Quarter Ended | | Half Year Ended | | Year Ended |
|---------|---------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 30/09/2021 (Unaudited) | 30/09/2020 (Unaudited) | 30/09/2021 (Unaudited) | 30/09/2020 (Unaudited) | 31/03/2021 (Audited) |
| 1 | Revenue from operations | 3,304 | 4,789 | 7,242 | 10,111 | 16,535 |
| 2 | Profit before tax | 523 | 865 | 1,433 | 2,481 | 3,922 |
| 3 | Net profit for the period/ year | 536 | 709 | 1,288 | 1,976 | 3,095 |
| 4 | Total comprehensive income | 513 | 770 | 1,352 | 2,042 | 3,228 |

- The above is an extract of the detailed format of Financial Results for the quarter and half year ended 30 September, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **November, 11, 2021**.
- The Board of Directors at their meeting held on November 11, 2021 have recommended an interim dividend of ₹ 0.50 per equity share of ₹2 each.

Place: Hyderabad
Date: November, 11, 2021

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

